Metabolic Factors May Contribute to Tx Resistance in Renal Cancer

This article originally appeared here.
Share this content:
Metabolic Factors May Contribute to Tx Resistance in Renal Cancer
Metabolic Factors May Contribute to Tx Resistance in Renal Cancer

THURSDAY, Aug. 4, 2016 (HealthDay News) -- Tumor cell-intrinsic metabolic factors may contribute to anti-programmed death 1 (PD-1)/PD-L1 treatment resistance in renal cell carcinoma (RCC), according to a study published online Aug. 4 in Cancer Immunology Research.

Maria Libera Ascierto, Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined mechanisms underlying the failure of PD-1-targeted therapies in patients with advanced RCC whose tumors express PD-L1. The authors derived formalin-fixed, paraffin-embedded pretreatment tumor biopsies expressing PD-L1 from 13 patients. RNA from PD-L1+ regions was subjected to whole genome microarray and multiplex quantitative real-time polymerase chain reaction gene expression analysis.

The researchers found that, following anti-PD-1 therapy, the balance between gene expression profiles reflecting metabolic pathways and immune functions correlated with clinical outcomes. In patients with PD-L1+ RCC, expression of genes involved in metabolic and solute transport functions correlated with treatment failure. Tumors from patients who responded to treatment overexpressed immune markers, including BACH2, which regulated CD4+ T cell differentiation, and CCL3, which was involved in leukocyte migration.

"These findings suggest that tumor cell-intrinsic metabolic factors may contribute to treatment resistance in RCC, thus serving as predictive markers for treatment outcomes and potential new targets for combination therapy regimens with anti-PD-1," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb, which funded the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Illicit Marijuana Use Up in States With Legal Medical Use

Illicit Marijuana Use Up in States With Legal ...

Cannabis use disorder is also rising faster in states with legalization laws

Chromosome Instability Test Prognostic in NSCLC

Chromosome Instability Test Prognostic in NSCLC

Chromosome instability associated with higher risk of relapse, death within 2 years

CDC: Opioid-Related Mortality Rate Might Be Underestimated

CDC: Opioid-Related Mortality Rate Might Be Underestimated

Death certificates from drug-linked infections may not label opioids as possible cause

is free, fast, and customized just for you!

Already a member?

Sign In Now »